Skip to Main Content

Paper Details

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.
Clin Cancer Res
33
2022
Author NameAffiliation
Michael MorrisseyMerck & Co., Inc.
Antoni RibasUniversity of California los angeles
Antoni RibasUniversity of California los angeles
David W CesconUHN Princess Margaret Cancer Centre
Andrey LobodaMerck & Co., Inc.
  • 1 - 5

Datasets

Release 1.2